Key Highlights

  • 60 percent: Monday's gain for PDS Biotechnology (NASDAQ:PDSB) on about 77.5 million shares to near USD 1.20, extending a one-month rise of about 325 percent, per published market data, with no same-day company release identified.
  • USD 11.3 million: the gross proceeds at the September 14, 2026 initial closing of a PIPE led by Nant Capital, issuing 16,502,870 shares, 23,498,156 pre-funded warrants and 20,000,514 common warrants, per the company's announcement of that date.
  • About USD 11 million more: the contingent milestone closing, triggered by submission of a registrational Phase 3 protocol for PDS0301 to the FDA, in a financing PDS Biotech (NASDAQ:PDSB) described as up to USD 22.3 million.
  • One year: the term of an exclusive right to negotiate a license to PDS0101 granted to NantWorks, an affiliate of Dr. Patrick Soon-Shiong, who joined the board with James Banaag at the initial closing of the financing.

The Financing Behind the Run

On September 8, 2026 PDS Biotech announced a financing of up to USD 22.55 million led by Dr. Patrick Soon-Shiong, and on September 14 it announced an initial closing of about USD 11.3 million. At that closing it issued 16,502,870 shares, 23,498,156 pre-funded warrants and 20,000,514 common warrants, about USD 0.28 per share or pre-funded warrant, simple arithmetic. That is far below Monday's price near USD 1.20. Dr. Soon-Shiong founded ImmunityBio, and the PIPE was led by his Nant Capital, with Dr. Soon-Shiong and Mr. Banaag joining the board.

Strategy and Science

The company has refocused on PDS0301, an IL-12 immunocytokine in solid tumors, and on a Partnership strategy for PDS0101 (Versamune HPV), granting NantWorks a one-year exclusive negotiation right. VERSATILE-003 is a Phase 3 trial of PDS0101 with pembrolizumab in HPV16-positive head and neck cancer, amended to add progression-free survival as an interim endpoint for potential accelerated approval. A VERSATILE-002 publication appeared on September 22, 2026. The earlier VERSATILE-002 Phase 2 trial supported the Fast Track Designation the FDA granted for PDS0101 with pembrolizumab in recurrent or metastatic head and neck cancer.

Why It Could Be Fragile

The move came with no same-day company release identified, and the stock had risen about 325 percent in a month, from lows near USD 0.20. Warrants and pre-funded warrants add potential shares, and the milestone closing depends on an FDA protocol submission. The company's forward-looking statements flag going-concern risk. A sharp run in a low-priced biotech can reverse quickly if financing or trial news disappoints. Pre-funded warrants carry a nominal exercise price, so they behave like shares once exercised.

Where Things Stand

The most likely explanation is momentum built on the Soon-Shiong financing, not a new same-day event. PDS Biotechnology (NASDAQ:PDSB) priced its initial PIPE closing near USD 0.28 per share equivalent in September, and the stock now trades near USD 1.20, so early investors hold large paper gains and warrants. The milestone closing and the Phase 3 protocol for PDS0301 are the next real tests. Next catalysts are the FDA protocol submission, any NantWorks license agreement and updates on the VERSATILE-003 enrollment restart, none of which has a confirmed date. The financing price is the reference point.